title: Electrolytes-Enriched Hemodiafiltration Solutions for Continuous Renal Replacement Therapy in Acute Kidney Injury: A Crossover Study.
abstract: OBJECTIVE
  To evaluate the capability of an electrolytes-enriched solution to prevent metabolic disorders during continuous veno-venous hemodiafiltration (CVVHDF).
  
  
  METHODS
  Serum biochemistry and clinical tolerance were compared during CVVHDF treatments with an electrolyte-enriched (Phoxilium) or standard solutions in 10 acute renal failure patients.
  
  
  RESULTS
  As compared to standard fluids, serum potassium and phosphate levels were maintained in the normal range with Phoxilium without any supplementation but total serum calcium levels were significantly lower. Bicarbonatemia was slightly higher (24-26 vs. 21.5-24.5 mmol/l, p < 0.05) with conventional solutions and was associated with a significant increased level of pH (>7.44). Despite the absence of glucose in the Phoxilium solution, blood glucose levels and glucose supplementation were similar between treatments. Clinical tolerance and efficiency of CVVHDF sessions were comparable.
  
  
  CONCLUSIONS
  Phoxilium effectively prevented hypophosphatemia and hypokalemia during CVVHDF. It was, however, associated with a slight metabolic acidosis and hypocalcemia compared with conventional solutions.
authors.affiliation: Department of Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.
authors.forename: Noemie
authors.initials: N
authors.lastname: Besnard
authors.forename: Marianne
authors.initials: M
authors.lastname: Serveaux
authors.forename: Sonia
authors.initials: S
authors.lastname: Machado
authors.forename: Delphine
authors.initials: D
authors.lastname: Daubin
authors.forename: Vincent
authors.initials: V
authors.lastname: Brunot
authors.forename: Laurent
authors.initials: L
authors.lastname: Amigues
authors.forename: Liliane
authors.initials: L
authors.lastname: Landreau
authors.forename: Olivier
authors.initials: O
authors.lastname: Jonquet
authors.forename: Kada
authors.initials: K
authors.lastname: Klouche
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications / Q000628:therapy*; D000368:Aged; D018592:Cross-Over Studies; D004573:Electrolytes / Q000494:pharmacology / Q000627:therapeutic use; D017583:Hemodiafiltration / Q000009:adverse effects / Q000379:methods*; D015312:Hemodialysis Solutions / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007008:Hypokalemia / Q000517:prevention & control; D017674:Hypophosphatemia / Q000517:prevention & control; D008659:Metabolic Diseases / Q000209:etiology / Q000517:prevention & control*; D008875:Middle Aged; D017582:Renal Replacement Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D004573:Electrolytes; D015312:Hemodialysis Solutions